NCT03152305

Brief Summary

An increase in intracranial pressure (ICP) during migraine attacks is possible and could contribute to pain initiation and maintenance. From now on, it was not possible to measure ICP in a non-invasive way. The development of a new tool allows non-invasive self-measures of ICP variations. Thus, it is possible for the first time to look for such ICP variations during migraine attacks and to conclude if this mechanism is implied in the pathophysiology of migraine.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 21, 2014

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

May 11, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 15, 2017

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2018

Completed
Last Updated

May 15, 2017

Status Verified

May 1, 2017

Enrollment Period

2.8 years

First QC Date

May 11, 2017

Last Update Submit

May 11, 2017

Conditions

Keywords

MigraineIntracranial pressureHeadache

Outcome Measures

Primary Outcomes (1)

  • Intracranial pressure variations

    Measured during menstrual migraine attacks compared to ICP in non-migraine days and in matched healthy women

    during menstrual migraine attacks

Secondary Outcomes (2)

  • Relationships between ICP variations and clinical parameters

    during menstrual migraine attacks

  • Relationships between ICP variations and pain relief

    during menstrual migraine attacks

Study Arms (2)

Women with menstrual migraine

Womens presenting with regular menstrual migraine treated with triptans will be included in the study.

Other: Intracranial pressure variations

Matched control

The potential variations will be compared to the measures done on matched healthy women outside and during menses.

Other: Intracranial pressure variations

Interventions

Self-measure of ICP will be performed outside and during menstrual migraine attacks.

Matched controlWomen with menstrual migraine

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Womens presenting with regular menstrual migraine treated with triptans will be included in the study. Self-measure of ICP will be performed outside and during menstrual migraine attacks. The potential variations will be compared to the measures done on matched healthy women outside and during menses.

You may qualify if:

  • to 50 non menopausal women
  • Menstrual migraine
  • Using a triptan as usual treatment to relieve attacks
  • Usual triptan efficacy although recurrence is possible

You may not qualify if:

  • Disease of the ear
  • Intracranial hypertension
  • Chronic daily headache
  • Use of topiramate or acetazolamide
  • Triptans used more than 10 days/month
  • Analgesic drug used more than 15 days/month
  • Uncontrolled high blood pressure
  • BMI \>30
  • Ongoing allergic rhinitis or flu

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Clermont-Ferrand

Clermont-Ferrand, Auvergne, 63003, France

RECRUITING

MeSH Terms

Conditions

Migraine DisordersHeadache

Condition Hierarchy (Ancestors)

Headache Disorders, PrimaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 11, 2017

First Posted

May 15, 2017

Study Start

July 21, 2014

Primary Completion

May 1, 2017

Study Completion

July 1, 2018

Last Updated

May 15, 2017

Record last verified: 2017-05

Locations